Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)
Year: 2024
Type: conference-abstract
Source: Blood
Authors: Austin I. Kim, Philippe Armand, Christine E. Ryan, Robert A. Redd, Megan Forsyth, Juniper Mai, Samantha Pazienza, Caitlin Bresnahan, Vanessa M Kats, Salah Abdulkarim, Susan M Waisgerber, Reid W. Merryman, David C. Fisher, Inhye E. Ahn, Jennifer L. Crombie, Oreofe O. Odejide, Ann S. LaCasce, Caron A. Jacobson, Eric D. Jacobsen, Erin M. Parry, David A. Qualls, Amy C. Bessnow, Matthew S. Davids, Jennifer R. Brown, Jon E. Arnason, Michael Leukam, Peter A. Riedell, Mark A. Murakami
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405045633
